Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | NADK | O95544 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5981546 | 0.89 | HIF1A (0.52) | HIF1AADORA3ADORA2APIM1CSNK2A2 | |
| SCHEMBL5981544 | 0.89 | HIF1A (0.52) | HIF1AADORA3ADORA2APIM1CSNK2A2 | |
| SCHEMBL31685786 | 0.88 | ADORA3 (0.52) | HIF1AADORA3ADORA2APIM1CSNK2A2 | |
| SCHEMBL5983124 | 0.88 | ADORA3 (0.52) | HIF1AADORA3ADORA2APIM1CSNK2A2 | |
| SCHEMBL5983113 | 0.88 | ADORA3 (0.52) | HIF1AADORA3ADORA2APIM1CSNK2A2 | |
| SCHEMBL14234076 | 0.88 | ADORA3 (0.50) | HIF1AADORA3ADORA2APIM1CSNK2A2 | |
| SCHEMBL24420987 | 0.87 | ADORA2A (0.64) | HIF1AADORA3ADORA2APNPLMNA | |
| SCHEMBL14253676 | 0.87 | ADORA2A (0.64) | HIF1AADORA3ADORA2APNPLMNA | |
| SCHEMBL659995 | 0.87 | ADORA2A (0.64) | HIF1AADORA3ADORA2APNPLMNA | |
| SCHEMBL440599 | 0.87 | ADORA2A (0.64) | HIF1AADORA3ADORA2APNPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044228-B1 | HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH | CHEMGENES CORP (US) | 2021-04-07 | — | — | EP | disclosed |
| CN-105916873-B | Efficient synthesis of long RNAs using the reverse method | 坎姆根公司 | 2020-06-19 | — | — | CN | disclosed |
| US-10167308-B2 | Highly efficient synthesis of long RNA using reverse direction approach | CHEMGENES CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| US-9969764-B2 | Dithiolane functionalized nucleoside amidites and supports for stronger immobilization of bio-molecules on solid surfaces | CHEMGENES CORPORATION | 2018-05-15 | — | — | US | disclosed |
| US-9884885-B2 | Synthesis of labile base protected-modified deoxy and modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis | CHEMGENES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| US-9605261-B2 | RNA synthesis—phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end | CHEMGENES CORPORATION (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170037076-A1 | DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID SURFACES | CHEMGENES CORPORATION | 2017-02-09 | — | — | US | disclosed |
| EP-2326656-B1 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORP (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-3060572-A1 | DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID SURFACES | Chemgenes Corporation (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-3044228-A2 | HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH | Chemgenes Corporation (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20130072670-A1 | RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END | CHEMGENES CORPORATION (US) | 2013-03-21 | — | — | US | disclosed |
| US-8309707-B2 | RNA synthesis-phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end | CHEMGENES CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120065386-A1 | SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION | 2012-03-15 | — | — | US | disclosed |
| EP-2326656-A2 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | Chemgenes Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20110015382-A1 | Synthesis of N-FMOC protected deoxy nucleosides, ribo nucleosides, modified deoxy and ribo nucleosides, and phosphoramidites, and their use in oligonucleotide synthesis | CHEMGENES CORPORATION (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100324278-A1 | RNA synthesis-phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3'-end | CHEMGENES CORPORATION | 2010-12-23 | — | — | US | disclosed |
| WO-2010134992-A2 | SYNTHESIS LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010062404-A2 | N-FMOC NUCLEOSIDES AND PHOSPHORAMIDITES, AND OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010027512-A9 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORPORATION (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010027512-A2 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015382-A1 | Synthesis of N-FMOC protected deoxy nucleosides, ribo nucleosides, modified deoxy and ribo nucleosides, and phosphoramidites, and their use in oligonucleotide synthesis | RNGTT, RNMT, NSUN2 | HIF1A 1195/4885ADORA3 612/4885ADORA2A 880/4885 |
| US-20120065386-A1 | SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | RNMT, POLRMT, RNGTT | HIF1A 1845/4885ADORA3 451/4885ADORA2A 153/4885 |
| US-20100324278-A1 | RNA synthesis-phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3'-end | NSUN3, RNMT, NSUN2 | HIF1A 4457/4885ADORA3 102/4885ADORA2A 458/4885 |
| US-20130072670-A1 | RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END | NSUN3, RNMT, NSUN2 | HIF1A 4457/4885ADORA3 102/4885ADORA2A 458/4885 |
| US-10167308-B2 | Highly efficient synthesis of long RNA using reverse direction approach | NSUN3, POLRMT, METTL16 | HIF1A 4488/4885ADORA3 3052/4885ADORA2A 4599/4885 |
| US-20170037076-A1 | DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID SURFACES | RNGTT, DIMT1, ADAR | HIF1A 3260/4885ADORA3 1655/4885ADORA2A 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.